Skip to content
Ansun Biopharma Logo Ansun Biopharma Logo
  • ABOUT
    • Who We Are
    • Leadership Team
    • Board of Directors
  • RESEARCH & TECHNOLOGIES
    • Respiratory Disease
    • DAS181 Biology
    • Solid Tumors
  • PIPELINE
  • CLINICAL TRIALS
  • INVESTORS & NEWS
  • CAREERS
  • CONTACT

Ansun BioPharma secures $85 million in Series A Financing

Previous Next

Ansun BioPharma secures $85 million in Series A Financing

By abadmin|2021-08-26T07:17:44+00:00May 18th, 2018|Uncategorized|0 Comments

Share This Story, Choose Your Platform!

FacebookXRedditLinkedInWhatsAppTumblrPinterestVkEmail

About the Author: abadmin

Related Posts

Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection

Ansun Biopharma Announces First Patient Enrolled In Phase 3 Clinical Trial Evaluating DAS181 In Hospitalized, Immunocompromised Patients With Lower Respiratory Tract Parainfluenza Virus Infection

Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181

Ansun BioPharma Announces Breakthrough Designation for its Experimental Drug DAS181

Leave A Comment Cancel reply

10045 Mesa Rim Road
San Diego, CA 92121 U.S.A.

Tel: (858) 452-2631

Page load link
Go to Top